Galectin Therapeutics (NASDAQ: GALT)
Galectin Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Galectin Therapeutics Company Info
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
News & Analysis
3 Stocks That Could Double Your Money
Find out why these three biotech stocks could be huge winners.
Why Galectin Therapeutics Stock Bolted Higher Today
Galectin's new patent for its lead drug candidate sent its shares higher today.
2 Clinical-Stage Biotech Stocks That Could Soar Next Week
Shares of Galectin Therapeutics and Verastem should both head higher in the coming week. Here's why.
3 NASH Stocks That Could Soar in the Second Half of 2018
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
Why Galectin Therapeutics Inc. Shares Jumped
Galectin shares soar following the company's dosing of its first patient in a second phase 1 cohort. Here's what shareholders should really be watching.
Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks
Consumer confidence hits a six-year high, adding fuel to the huge run-ups for Plug Power, Varonis Systems, and Galectin Therapeutics.
Why Galectin Therapeutics, Inc. Shares Soared
Galectin sets the date for the release of its phase 1 study data on GR-MD-02 for nonalcoholic steatohepatitis. Find out what shareholders should really be waiting for.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar Therapeutics
Top stories in biotech and healthcare today.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.